Race Oncology CEO/MD Phil Lynch speaks to Matt Birney of the Bulls n' Bears Report…
For all the excitement about curing cancer or the disease going into remission, the relief for some patients can often be short-lived if the treatment leaves them with other potentially long-term health repercussions.
Cardiovascular health problems are typically the most common, but Race Oncology (ASX:RAC) is working to minimise damage to the heart linked to almost all cancer therapies with its core asset bisantrene. Read more here.